Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ACLX-001 |
Synonyms | |
Therapy Description |
ACLX-001 is a cell therapy comprising SPRX-001, a soluble protein targeting TNFRSF17 (BCMA), and Antigen Receptor Complex T-cells (ARC T-cells), which potentially induces antitumor activity (Cancer Res (2021) 81 (13_Supplement): 1549). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ACLX-001 | ACLX001|ACLX 001 | ACLX-001 is a cell therapy comprising SPRX-001, a soluble protein targeting TNFRSF17 (BCMA), and Antigen Receptor Complex T-cells (ARC T-cells), which potentially induces antitumor activity (Cancer Res (2021) 81 (13_Supplement): 1549). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04155749 | Phase I | CART-ddBCMA ACLX-001 | Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | Active, not recruiting | USA | 0 |